New Combo Therapy Offers Hope for 693 Crohn's Patients

For people living with inflammatory bowel disease who've watched treatment after treatment fail, two new clinical trials just delivered something precious: real hope.

Researchers tested a combination of two existing drugs on patients who had already exhausted multiple treatment options. The results presented at Digestive Disease Week in Chicago showed that 49.2% of the most treatment-resistant Crohn's disease patients achieved clinical remission after 48 weeks, compared to just 23-27% on single drugs.

Up to 3.1 million Americans live with inflammatory bowel disease, a lifelong condition where the immune system attacks healthy intestinal cells. Symptoms include severe diarrhea, stomach pain, fatigue, and unintended weight loss that can make daily life unbearable.

The trials focused on patients with moderate-to-severe disease who'd already failed one or more drug therapies. One study followed 693 people with Crohn's disease, while the other tracked 572 patients with ulcerative colitis, the two main types of the condition.

The experimental therapy combined golimumab and guselkumab, two drugs already on the market that target different inflammation-causing proteins. By attacking the disease from two angles simultaneously, doctors achieved results that single drugs couldn't deliver alone.

Tess Koman knows this struggle intimately. The 34-year-old food writer has endured 20 abdominal surgeries for Crohn's disease since her diagnosis at age seven, and she's left with only half her bowel remaining.

"I have such a varied track record with different classes of drugs either being OK for a bit or not OK at all," Koman explained. For patients like her who face surgery as their last option, combination therapies could preserve their remaining healthy tissue.

The Ripple Effect

While these are still Phase 2b trials requiring larger Phase 3 studies to confirm the findings, doctors are already taking notice. An estimated 10 to 20% of inflammatory bowel disease patients eventually fail two or more advanced therapies, leaving them with limited options beyond surgery.

Dr. Maria Abreu, who led the ulcerative colitis study, believes doctors will start considering combination therapies for struggling patients once they learn about these results. Some specialists already try prescribing multiple medications, though convincing insurance companies to approve dual therapy remains challenging.

The good news? Since both drugs already exist on the market, doctors can prescribe them individually while the combination therapy completes clinical trials. Phase 3 trials are expected to begin recruiting patients later this year.

For hundreds of thousands of Americans watching their quality of life diminish as treatments stop working, this research represents more than just promising data on a chart.